Abstract P4-21-06: Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: A subanalysis of data from the randomized phase III GeparSepto trial

@inproceedings{Uleer2017AbstractPD,
  title={Abstract P4-21-06: Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: A subanalysis of data from the randomized phase III GeparSepto trial},
  author={Christoph Uleer and Josephine Jackisch and Andreas Schneeweiss and Sabine Schmatloch and Bahriye Aktas and Carsten Denkert and Christian Schem and Hermann Wiebringhaus and Sherko K{\"u}mmel and Kristina Luebbe and Mathias R. Warm and Marianne Just and Sarah Hrebien and John Hackmann and Ju Blohmer and Michael R. Clemens and K. H. Engels and Valentina Nekljudova and Gunter von Minckwitz},
  year={2017}
}
Background Our recent randomized, multicenter phase III GeparSepto study (Untch M et al. Lancet Oncol 2016) found that substituting nab-paclitaxel for standard solvent-based paclitaxel significantly improved the pathologic complete response (pCR) rate in patients receiving a sequential regimen of taxane, epirubicin and cyclophosphamide as neoadjuvant treatment for high-risk primary breast cancer. Patients with HER2-positive tumors (32.8%; n=396) also received a combination of pertuzumab and… CONTINUE READING

Topics from this paper.

Similar Papers

Loading similar papers…